# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM

# E. Applicant:

# F. Proprietary and Established Names:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 6 . 5 7 5 0$ , Radioallergosorbent (RAST) immunological test system

2. Classification: Class II

3. Product code: MST –Antibodies, Gliadin

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended uses:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:

Enzyme linked immunosorbent assays (ELISA) for the qualitative or semi-quantitative detection of IgA anti-gliadin antibodies in human serum to aid in the diagnosis of patients with celiac disease or dermatitis herpetiformis in conjunction with other laboratory and clinical findings.

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:

Enzyme linked immunosorbent assays (ELISA) for the qualitative or semi-quantitative detection of IgG anti-gliadin antibodies in human serum to aid in the diagnosis of patients with celiac disease or dermatitis herpetiformis in conjunction with other laboratory and clinical findings.

2. Indication(s) for use: Same as intended use

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements:

An ELISA microplate reader capable of reading absorbance values at $4 5 0 \mathrm { n m }$ . If a dual wavelength microplate reader is available, the reference filter should be set at $4 5 0 / 6 5 0 \mathrm { n m }$ . An automatic microplate washer capable of accurately dispensing $2 0 0 \mu \mathrm { L }$ of fluid is also required.

# I. Device Description:

Each kit consists of $1 2 \times 8$ -antigen coated microwell strips, negative control ( $1 \mathrm { x } 1 . 7 5 \mathrm { m L }$ ), positive control $\mathrm { ( 1 x ~ 1 . 7 5 ~ m L ) }$ ), five assay calibrators $( 5 \mathrm { x } \ 1 . 7 5 \ \mathrm { m L }$ ), horseradish peroxidase anti-human IgA or IgG conjugate $\mathrm { 1 x ~ 1 5 ~ m L }$ ), TMB enzyme substrate $\mathrm { 1 x ~ 1 5 ~ m L }$ ), stop solution $\mathrm { 1 x ~ 1 5 ~ m L }$ ), wash buffer (2 vials) and diluent $\mathrm { 1 x 6 0 m L }$ ). The results are read by a spectrophotometer at $4 5 0 \mathrm { n m }$ . Results are expressed in ELISA units per milliliter $\mathrm { ( E U / m L ) }$ ) and reported as positive or negative.

# J. Substantial Equivalence Information:

1. Predicate device names and 510(k) numbers: Immco Anti-Gliadin Antibody (AGA) IgA ELISA (IgA-AGA), K964341 Immco Anti-Gliadin Antibody (AGA) IgG ELISA (IgG-AGA), K964344

# 2. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New DeviceImmuLisaTM Enhanced Gliadin(IgA or IgG) Antibody ELISA</td><td rowspan=1 colspan=1>PredicateImmco Anti-Gliadin Antibody(IgA-AGA or IgG-AGA) ELISA</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Enzyme linked immunosorbent assays(ELISA) for the detection and semi-quantitation of IgA or IgG anti-gliadinantibodies in human serum to aid in thediagnosis of patients with celiac disease ordermatitis herpetiformis in conjunction withother laboratory and clinical findings.</td><td rowspan=1 colspan=1>Enzyme linked immunosorbentassays (ELISA) for the detectionand semi-quantitation of IgA or IgGanti-gliadin antibodies in humanserum to aid in the diagnosis ofpatients with celiac disease anddermatitis herpetiformis.</td></tr><tr><td rowspan=1 colspan=1>Assay Type</td><td rowspan=1 colspan=1>Manual ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Polystyrene microplate wells</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Capture Antigen</td><td rowspan=1 colspan=1>Purified native gliadin antigen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Format</td><td rowspan=1 colspan=1>Semi-quantitative and qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>20 EU/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Component set</td><td rowspan=1 colspan=1>Includes positive control, negative control,calibrators, conjugate, substrate, diluent,wash buffer, stop solution, microplate well.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Incubation Times</td><td rowspan=1 colspan=1>Positive and negative controls, dilutedpatient samples: 30 min.Conjugate: 30 min.Enzyme Substrate: 30 min (in the dark).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReactionTemperature</td><td rowspan=1 colspan=1>Room temperature</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>International Reference Preparation is notavailable. Results are traceable to in-housestandards.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>Gliadin IgA or Gliadin IgG antibodies</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Signal</td><td rowspan=1 colspan=1>Optical density</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>Microwell plate reader</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceImmuLisaTM Enhanced GliadinIgA or IgG Antibody ELISA</td><td colspan="1" rowspan="1">PredicateImmco Anti-Gliadin Antibody(IgA-AGA or IgG-AGA) ELISA</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Set of five:Values in EU/mL: 160, 80 40, 20, 1</td><td colspan="1" rowspan="1">Set of four:Varying EU/mL by kit lot</td></tr><tr><td colspan="1" rowspan="1">Labeled DetectionAntibody(Conjugate)</td><td colspan="1" rowspan="1">Horseradish peroxidase conjugated to goatanti-human IgA or IgG</td><td colspan="1" rowspan="1">Alkaline phosphatase conjugated togoat anti-human IgA or IgG</td></tr><tr><td colspan="1" rowspan="1">Enzyme Substrate</td><td colspan="1" rowspan="1">Tetramethylbenzidene</td><td colspan="1" rowspan="1">p-Nitrophenyl phosphate</td></tr><tr><td colspan="1" rowspan="1">Stop Solution</td><td colspan="1" rowspan="1">Sulfuric acid (H2SO4)</td><td colspan="1" rowspan="1">Ethylenediaminetetraacetic acid(EDTA)</td></tr><tr><td colspan="1" rowspan="1">Wash Buffer</td><td colspan="1" rowspan="1">Powdered or optional liquid concentrate</td><td colspan="1" rowspan="1">Liquid concentrate</td></tr><tr><td colspan="1" rowspan="1">Linear Range</td><td colspan="1" rowspan="1">IgA 7.5 EU/mL - 160 EU/mLIgG 4.6 EU/mL - 160 EU/mL</td><td colspan="1" rowspan="1">Not specified</td></tr><tr><td colspan="1" rowspan="1">Limit of Detection</td><td colspan="1" rowspan="1">IgA 2.6 EU/mLIgG 2.8 EU/mL</td><td colspan="1" rowspan="1">Not specified</td></tr><tr><td colspan="1" rowspan="1">Sample dilution</td><td colspan="1" rowspan="1">1:101</td><td colspan="1" rowspan="1">1:51</td></tr><tr><td colspan="1" rowspan="1">Reading onspectrophotometer</td><td colspan="1" rowspan="1">450 nm</td><td colspan="1" rowspan="1">405 nm</td></tr><tr><td colspan="1" rowspan="1">ResultsInterpretation</td><td colspan="1" rowspan="1">Negative: &lt; 20 EU/mLIndeterminate: 20-25 EU/mLPositive: &gt; 25 UE/mL</td><td colspan="1" rowspan="1">Adults:Both IgA and IgGNegative: ≤ 20 EU/mLPositive: &gt; 20 EU/mLChildren:IgANegative: ≤ 23 EU/mLPositive: &gt; 23 EU/mLIgGNegative: ≤ 28 EU/mLPositive: &gt; 28 EU/mL</td></tr></table>

# K. Standard/Guidance Document Referenced:

CLSI guideline EP05-A2, “Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline ̶ Second Edition”

CLSI guideline EP06-A, “Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline”

CLSI guideline EP07-A2, “Interference Testing in Clinical Chemistry; Approved Guideline–Second Edition”

CLSI guideline EP09-A2, “Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline.”

CLSI guideline EP12-A2, “User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline–Second Edition”

CLSI guideline EP17-A2, “Evaluation of Detection Capability for Clinical. Laboratory Measurement Procedures; Approved Guideline–Second Edition”

# L. Test Principle:

The test is performed as a solid phase immunoassay. Gliadin antigen is bound to the wells of a polystyrene microwell plate followed by blocking the unreacted sites to reduce non-specific binding. Controls, calibrators and patient sera are added to separate wells, allowing any gliadin antibodies present to bind to the immobilized antigen. Unbound antibodies and other serum proteins are removed by washing the microplate wells. Bound antibodies are detected by adding an enzyme labeled anti-human IgA or IgG conjugate to the microplate wells. These enzyme conjugated antibodies bind specifically to the human immunoglobulin of the appropriate class. After washing away any unbound conjugate, specific enzyme substrate (TMB) is then added to the wells and the presence of antibodies is detected by a color change produced by the conversion of TMB substrate to a colored reaction product. After stopping the enzymatic reaction, the intensity of color change, which is proportional to the concentration of antibody, is read by a spectrophotometer at $4 5 0 \mathrm { n m }$ . Results are expressed in ELISA units per milliliter $\mathrm { ( E U / m l ) }$ and reported as positive or negative.

Semi-quantitative results are determined from a series of five calibrators (160 EU/mL, $8 0 ~ \mathrm { E U / m L }$ , 40 $\mathrm { E U / m L }$ , $2 0 \ : \mathrm { E U / m L }$ , and $1 \mathrm { E U / m L }$ ). Values less than $2 0 \ : \mathrm { E U / m L }$ are considered negative results while values greater than $2 5 \mathrm { \ E U / m L }$ are considered positive; results between $2 0 \ : \mathrm { E U / m L }$ and $2 5 \mathrm { E U / m L }$ are considered ‘indeterminate/borderline’. The sponsor states the following recommendations in the Package Insert: “Indeterminate/borderline results should be retested and evaluated along with other laboratory methods, such as assays for detection of EMA and/or tTG antibodies”.

Qualitative results are determined using a ratio of the absorbance of the sample to the absorbance of the cutoff calibrator (20 EU/mL). The ratio is multiplied by the concentration of the cut-off calibrator to give a numerical value. Values greater than or equal to $2 0 \ : \mathrm { E U / m L }$ are considered positive and ${ < } 2 0 \ \mathrm { E U / m L }$ values are considered negative.

# M. Performance Characteristics:

1. Analytical performance:

a. Precision/Reproducibility:

Semi-Quantitative Precision:

Precision performance was evaluated in accordance with CLSI guideline EP05-A2 “Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline”. A panel consisting of seven patient sera with levels of gliadin antibodies that cover the analytical measuring range was assayed in duplicate, twice a day, for 20 days with one reagent lot (a total of 80 replicates per sample). Testing was performed by two operators using different equipment sets. The first operator performed the assay with a multi-channel pipettor (BioHit), microplate washer $\left( \operatorname { E L x } 4 0 5 \right)$ and microplate reader $\left( \operatorname { E L x } 8 0 8 \right)$ . The second operator used different instruments from the same type of equipment. All $\% \mathrm { C V }$ values were within the manufacturer’s pre-determined acceptance limit. The results are summarized in the table below for each assay:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Between-Runs</td><td rowspan=1 colspan=2>Between-Days</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>10.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>67.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>93.2</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>143.5</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>7.1</td></tr></table>

ImmuLisa™ Enhanced Gliadin $\mathrm { I g G }$ Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Between-Runs</td><td rowspan=1 colspan=2>Between-Days</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>9.9</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>19.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>23.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>44.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>96.8</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>8.8</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>153.4</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>8.7</td></tr></table>

# Qualitative Reproducibility:

Studies were performed under the guidance of CLSI EP12-A2 ‘User Protocol for Evaluation of Qualitative Test Performance.’ Eighty replicates of each patient serum in the negative range, ${ \sim } 2 0 \%$ below cut-off, at \~cut-off, ${ \sim } 2 0 \%$ above cut-off and in the moderate positive range of the assays were performed to determine intra-assay qualitative reproducibility. Results were calculated using singlepoint (qualitative) analysis as indicated in the product insert. All values for qualitative agreement were within the manufacturer’s pre-determined acceptance limit. Results are summarized below.

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=2 colspan=1>Totalreplicates</td><td rowspan=1 colspan=2>Qualitative Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive/negative</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Cut-off-20%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>20.2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>41/39</td><td rowspan=1 colspan=1>51.3</td></tr><tr><td rowspan=1 colspan=1>Cut-off +20%</td><td rowspan=1 colspan=1>24.3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>67.5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate to High Positive</td><td rowspan=1 colspan=1>83.1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>102.8</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr></table>

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=2 colspan=1>Totalreplicates</td><td rowspan=1 colspan=2>Qualitative Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive/negative</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Cut-off-20%</td><td rowspan=1 colspan=1>17.1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>46/34</td><td rowspan=1 colspan=1>57.5</td></tr><tr><td rowspan=1 colspan=1>Cut-off +20%</td><td rowspan=1 colspan=1>23.4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>51.7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate to High Positive</td><td rowspan=1 colspan=1>64.7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>82.9</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td><td rowspan=1 colspan=1>100</td></tr></table>

# Lot-to-lot Reproducibility:

To evaluate lot-to-lot reproducibility, a panel of five samples with levels of gliadin antibodies spanning the assay range was tested in replicates of five on three different lots over the course of five days. All $\% \mathrm { C V }$ values were within the manufacturer’s pre-determined acceptance limit. The results are summarized in the table below for each assay:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Lots</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>35.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>77.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>149.7</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>7.8</td></tr></table>

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Lots</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16.13</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22.59</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>9.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>35.48</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>87.31</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>122.87</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>9.2</td></tr></table>

# Site-to-site Reproducibility:

To evaluate site-to-site reproducibility, a panel of five samples with levels of gliadin antibodies spanning the assay range was tested in replicates of five at three different sites over the course of five days using one lot of reagent. All $\% \mathrm { C V }$ values were within the manufacturer’s predetermined acceptance limit. The results are summarized in the table below for each assay:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Sites</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>47.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>88.4</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>9.6</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>146.2</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>8.8</td></tr></table>

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Sites</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>9.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>24.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>33.9</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>70.0</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>151.1</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>9.2</td></tr></table>

# $b$ . Linearity/assay reportable range:

Linearity and recovery were tested by diluting positive specimens across the measuring range in equidistant dilutions with negative patient sera. The observed values were graphed against the calculated values and a linear regression was performed. Results summarized in the table below were within the manufacturer’s pre-determined acceptance criteria of recovery.

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Dilution Range(EU/mL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Y-Intercept(95% CI)</td><td rowspan=1 colspan=1>$R^2$</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=3 colspan=1>b</td><td rowspan=1 colspan=1> </td><td rowspan=1 colspan=1>B2GP1 1gG Qualitativo Rregision:</td><td rowspan=1 colspan=1>1.01(0.92 to 1.10)</td><td rowspan=1 colspan=1>1.13(-1.14 to 3.39)</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>92% to 94%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.3 to 97.2</td><td rowspan=1 colspan=1>1.04(0.95 to 1.12)</td><td rowspan=1 colspan=1>1.45(-3.18 to 6.08)</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>90% to 96%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4.7 to 127.4</td><td rowspan=1 colspan=1>0.85(0.79 to 0.91)</td><td rowspan=1 colspan=1>2.06(-3.39 to 7.41)</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>102% to 117%</td></tr></table>

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Dilution Range(EU/mL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Y-Intercept(95% CI)</td><td rowspan=1 colspan=1>$R^{2</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9.0 to 47.0</td><td rowspan=1 colspan=1>0.98(0.88 to 1.08)</td><td rowspan=1 colspan=1>0.87(-2.16 to 3.90)</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>93% to 106%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12.7 to 116.8</td><td rowspan=1 colspan=1>0.98(0.91 to 1.05)</td><td rowspan=1 colspan=1>-1.47(-6.66 to 3.73)</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>102% to 110%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>58.1 to 147.4</td><td rowspan=1 colspan=1>0.98(0.87 to 1.08)</td><td rowspan=1 colspan=1>3.67(-7.70 to 15.04)</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>98% to 106%</td></tr></table>

The linear range was determined to be $7 . 5 { - } 1 6 0 \ \mathrm { E U / m L }$ for the gliadin IgA assay and 4.6–160 EU/mL for the gliadin IgG assay. For test results above 160 EU/mL, the package insert recommends dilution and retesting of the samples.

High dose hook effect: Four high concentrations specimens were serially diluted 1:100 to assess the presence of any artefactual decrease in assay signal associated with gliadin antibody excess (hook effect). No hook effect was demonstrated in dilution sample levels up to $5 5 1 5 . 8 \mathrm { E U / m L }$ of gliadin IgA and $1 6 8 6 . 3 \mathrm { E U / m L }$ of gliadin IgG.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

i. Traceability:

There are currently no recognized international standards for the measurement of gliadin antibodies. Calibrator and Control values are directly traceable to in-house standards.

# ii. Value Assignment:

Calibrators and positive controls are dilutions of pooled gliadin antibody positive sera obtained from various commercial plasma centers. The calibrators and controls are taken from different pooled sera. In order to have traceability with newly made calibrators, each new lot of calibrators is assayed on an already cleared kit and compared to the existing calibrators as reference. Each lot of calibrator is also tested in comparison with normal human sera, clinical samples and internal standards. Five calibrator levels (Cal A-E) with assigned values from $0 { - } 1 6 0 \ \mathrm { E U / m L }$ are included to provide semi-quantitation and must be used with each run. The cut-off calibrator for the qualitative analysis is derived from Cal D. Test results greater than or equal to Cal D are considered positive.

For semi-quantitative determinations the positive controls must give values in the range stated on the vial. The negative control contains negative human serum in buffer. The negative control must be ${ < } 1 0 \ \mathrm { E U / m L }$ .

# iii. Stability:

Shelf-life Stability:

Accelerated and real-time stability studies for each ImmuLisa™ Enhanced Gliadin Antibody ELISA were conducted on three lots of components/reagents. The accelerated stability study was conducted with materials incubated at $3 7 ^ { \circ } \mathrm { C }$ . Data from the accelerated stability study set the shelf-life stability at 18 months. A real-time stability study is on-going and currently supports an 18-month shelf-life stability claim.

# Open Kit Stability:

For the open kit stability study, materials in each ImmuLisa™ Enhanced Gliadin Antibody ELISA are opened and stored in a dark environment as required for bench-top usage, then assayed at 15, 45 and 90 day intervals. Data from the open kit stability study demonstrate that

opened reagents are stable at 45 days, but the sponsor chose a more restrictive one month open kit stability claim.

# Sample Stability and Storage:

The package insert recommends that sera be assayed soon after separation or stored in aliquots at $2 { - } 8 ^ { \circ } \mathrm { C }$ for no longer than one week. For longer storage, serum specimens should be frozen. Avoid repeated freezing and thawing of samples. It is recommended that frozen specimens be tested within one year.

# d. Detection limit:

The analytical sensitivity was determined in accordance with CLSI EP17-A2. The Limit of Blank (LoB) was determined by assaying a blank sample in 60 replicates. The limit of detection (LoD) was determined by assaying six low negative sera in ten replicates over three days using two reagent lots of each ImmuLisa™ Enhanced Gliadin Antibody ELISA. The Limit of Quantitation was determined by testing four low level samples in replicates of four over three days using two reagent lots. The claimed LoB, LoD and LoQ are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>ImmuLisaTMGliadinAntibody ELISAs</td><td rowspan=1 colspan=1>LoB(EU/mL)</td><td rowspan=1 colspan=1>LoD(EU/mL)</td><td rowspan=1 colspan=1>LoQ(EU/mL)</td></tr><tr><td rowspan=1 colspan=1>Gliadin IgA</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>Gliadin IgG</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.6</td></tr></table>

# e. Analytical specificity:

# i. Endogenous Interference:

Interference studies were performed according to CLSI EP07-A2 by testing five serum samples with gliadin antibody levels corresponding to the negative range, near the assay cutoff and in the low, moderate and high positive range. Each sample was mixed with known quantities of potentially interfering substances and analyzed in one assay run with two replicates on one kit lot of each assay. The recovery was calculated by comparing to control samples spiked with the same volume of diluents. No significant interference was demonstrated in the ImmuLisa™ Enhanced Gliadin Antibody ELISAs with the following substances up to the concentrations listed in the table below:

<table><tr><td rowspan=1 colspan=1>Potential Interfering Compound</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>2 g/L</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>342 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>37 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>100 EU/mL</td></tr><tr><td rowspan=1 colspan=1>Total cholesterol</td><td rowspan=1 colspan=1>13 mmol/L</td></tr></table>

The ‘Limitations of Procedure’ section of the Package Insert states “This test should not be performed on grossly hemolyzed, microbially contaminated or lipemic samples”.

# ii. Cross-reactivity:

Numerous potentially cross-reactive autoimmune and infectious disease sera were tested for gliadin antibody levels. Refer to test results for 456 serum samples from patients in the NonTarget Disease Group in the table presented in the section below on Clinical studies. The number of serum samples tested positive is 12 $( 2 . 4 \% )$ for gliadin $\mathrm { I g A }$ and 21 $( 4 . 6 \% )$ for gliadin IgG. The ‘Limitations of Procedure’ section of the Package Insert states: “The results obtained serve only as an aid in the diagnosis and should not be interpreted as diagnostic in themselves.”

# f. Assay cut-off:

The assay cut-offs for the ImmuLisa™ Enhanced Gliadin Antibody ELISAs were determined by testing specimens from 126 healthy blood donors. Using the 97.5th percentile value of the results obtained, an arbitrary value of 20 EU/mL was assigned for the cut-off.

<table><tr><td>Gliadin antibody value</td><td>Result interpretation</td></tr><tr><td>&lt;20 EU/mL</td><td>Negative</td></tr><tr><td>2025 EU/mL</td><td>Indeterminate (Borderline)</td></tr><tr><td>&gt;25 EU/mL</td><td>Positive</td></tr></table>

Utilizing the $2 0 \ : \mathrm { E U / m L }$ cut-off value, $4 . 2 \%$ (5/120) and $1 . 7 \%$ (2/120) of the samples from healthy blood donors and patients in the Non-Target Disease Group were positive for gliadin IgA and gliadin IgG, respectively

# 2. Comparison studies:

# a. Method comparison with predicate devices:

For analysis of agreement with a predicate device, clinically defined serum samples from the target disease group and non-target disease group were assayed for each gliadin antibody on both ImmuLisa™ Enhanced Gliadin Antibody ELISA and Anti-Gliadin (AGA) ELISA. The diagnosed conditions in each group and the numbers of specimens tested for each gliadin antibody are presented in the table below:

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Gliadin IgA</td><td colspan="1" rowspan="1">Gliadin IgG</td></tr><tr><td colspan="1" rowspan="1">Target Disease Group</td><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Celiac Diseaseb (CD)</td><td colspan="1" rowspan="1">135</td><td colspan="1" rowspan="1">136</td></tr><tr><td colspan="1" rowspan="1">IgA Deficient CD (Adult)</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">IgA Deficient CD (Pedriatic)</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">Pediatric Celiac Disease</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">37</td></tr><tr><td colspan="1" rowspan="1">Dermatitis Herpetiformis</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">27</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">230</td><td colspan="1" rowspan="1">246</td></tr><tr><td colspan="1" rowspan="1">Non-Target Disease Group</td><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Systemic Lupus Erythematosus</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">23</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">Systemic Sclerosis</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Hashimoto's Thyroiditis</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Graves's Disease</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Crohn's Disease</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">Ulcerative Colitis</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Toxoplasmosis</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Herpes Simplex Virus 1</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">Herpes Simplex Virus 2</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">Rubella</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Lyme Disease</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">Helicobacter pylori</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="1">213</td></tr></table>

Only specimens in the linear range of the assays were included in the method comparison. Greater than $1 5 \%$ of the samples fell near the cutoff of both assays. The results for each assay are summarized below:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=2 colspan=3></td><td rowspan=1 colspan=2>AGA IgA ELISA (EU/mL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=3 colspan=2>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: &gt;25</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>113</td></tr><tr><td rowspan=1 colspan=1>by</td><td rowspan=1 colspan=1>Equivocal: 2025</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Negative: &lt;20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>262</td><td rowspan=1 colspan=1>265</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>400*</td></tr><tr><td rowspan=1 colspan=6>* target disease group (n=230) and non-target disease group (n=170)</td></tr></table>

Agreements were calculated by grouping ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA indeterminate results $( 2 0 { - } 2 5 \ \mathrm { E U / m L } )$ with its test negative results, and then agreements were calculated again by grouping Indeterminate results with the test positive results:

Indeterminate gliadin IgA results considered as negative:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>AGA IgA ELISA (EU/mL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: &gt;25</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>113</td></tr><tr><td rowspan=1 colspan=1>Negative: ≤25</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>274</td><td rowspan=1 colspan=1>287</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>400</td></tr><tr><td rowspan=1 colspan=5>Positive percent agreement: 88.1% (96/109)         95% CI: 80.1%-93.2%Negative percent agreement:94.2% (274/291)         95% CI: 90.6%-96.5%Total percent agreement:     92.5% (370/400)         95% CI : 89.5%-94.7%</td></tr></table>

Indeterminate gliadin IgA results considered as positive:

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>AGA IgA ELISA (EU/mL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: ≥20</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>135</td></tr><tr><td rowspan=1 colspan=1>Negative: &lt;20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>262</td><td rowspan=1 colspan=1>265</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>400</td></tr><tr><td rowspan=1 colspan=5>Positive percent agreement: 97.2% (106/109)        95% CI: 91.6%-99.3%Negative percent agreement: 90.0% (262/291)        95% CI: 85.9%93.1%Total percent agreement:     92.0% (368/400)        95% CI: 88.9%94.3%</td></tr></table>

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>AGA IgG ELISA (EU/mL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=3 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: &gt;25</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Equivocal: 20-25</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Negative: &lt;20</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>246</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>254</td><td rowspan=1 colspan=1>459*</td></tr><tr><td rowspan=1 colspan=5>* target disease group(n=246) and non-target disease group (n=213)</td></tr></table>

Agreements were calculated by grouping ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA indeterminate results $( 2 0 { - } 2 5 \mathrm { E U / m L } )$ with its test negative results, and then agreements were calculated again by grouping indeterminate results with the test positive results:

Indeterminate gliadin IgG results considered as negative:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>AGA IgG ELISA (EU/mL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: &gt;25</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Negative: ≤25</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>259</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>254</td><td rowspan=1 colspan=1>459</td></tr><tr><td rowspan=1 colspan=5>Positive percent agreement: 92.7% (190/205)        95% CI:88.0%-95.7%Negative percent agreement:96.1% (244/254)         95% CI: 92.7%98.0%Total percent agreement:     94.6% (444/459)         95% CI : 92.1%-96.3%</td></tr></table>

Indeterminate gliadin IgG results considered as positive:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>AGA IgG ELISA (EU/mL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>199</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>203</td></tr><tr><td rowspan=1 colspan=1>Negative: ≤20</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>246</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>254</td><td rowspan=1 colspan=1>459</td></tr><tr><td rowspan=1 colspan=5>Positive percent agreement: 97.1% (199/205)        95% CI: 93.4%98.8%Negative percent agreement:94.5% (240/254)        95% CI: 90.7%96.8%Total percent agreement:     95.6% (439/459)         95% CI: 93.4%-97.2%</td></tr></table>

b. Matrix comparison:

Not applicable since human serum is the only claimed specimen matrix. The ‘Specimen Collection and Handling’ section in the Package Insert states “Only serum specimens should be used in this procedure”.

3. Clinical studies:

# a. Clinical sensitivity and specificity:

A total of 751 serum samples were included in the clinical validation for the ImmuLisa™ Enhanced Gliadin Antibody ELISAs. The validation set of samples includes a target disease group (250 celiac disease and 45 dermatitis herpetiformis) and a non-target disease group (456 samples from patients with autoimmune and infectious conditions expected to be found in the intended use population). Test results for each disease group are shown below:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Gliadin IgA</td><td rowspan=1 colspan=2>Gliadin IgG</td></tr><tr><td rowspan=1 colspan=1># Pos*</td><td rowspan=1 colspan=1>% Pos</td><td rowspan=1 colspan=1># Pos*</td><td rowspan=1 colspan=1>% Pos</td></tr><tr><td rowspan=1 colspan=1>Target Disease Group</td><td rowspan=1 colspan=5>EY</td></tr><tr><td rowspan=1 colspan=1>Celiac Disease</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>77</td></tr><tr><td rowspan=1 colspan=1>Pediatric Celiac Disease</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Dermatitis Herpetiformis</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>35.6</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>57.8</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>295</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>50.1</td><td rowspan=1 colspan=1>217</td><td rowspan=1 colspan=1>72.5</td></tr><tr><td rowspan=1 colspan=1>Non-Target Disease Group</td><td rowspan=1 colspan=5>EY</td></tr><tr><td rowspan=1 colspan=1>Systemic Lupus Erythematosus</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Granulomatosis with Polyangiitis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Arthritis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Systemic Sclerosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Hashimoto&#x27;s Thyroiditis</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>Graves&#x27;s Disease</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;s Disease</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Ulcerative Colitis</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Autoimmune Hepatitis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Primary Biliary Liver Cirrhosis</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Herpes Simplex Virus 1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Herpes Simplex Virus 2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Lyme&#x27;s Disease</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Helicobacter pylori</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=6>Pos: positive* Indeterminate samples were considered positive</td></tr></table>

The performance of each ImmuLisa™ Enhanced Gliadin Antibody ELISA was evaluated against the clinical diagnosis of celiac disease and dermatitis herpetiformis separately. In both evaluations, the clinical sensitivity and specificity were calculated by grouping the assay’s indeterminate results with its test negative results, and then sensitivity and specificity were calculated again by grouping the assay’s equivocal results with its test positive results.

The clinical sensitivity and specificity of the ImmuLisa™ Enhanced Gliadin Antibody ELISAs in this sample cohort are summarized in the following tables for celiac disease:

# ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Celiac Disease Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>ImmuLisaTMEnhanced Gliadin IgAAntibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>146</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>444</td><td rowspan=1 colspan=1>530</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>706*</td></tr><tr><td rowspan=1 colspan=5>* celiac disease (n=200), pedriatic celiac disease (n=50) and non-target disease group (n=456)</td></tr></table>

Indeterminate gliadin IgA results considered as negative:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Celiac Disease Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>146</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>449</td><td rowspan=1 colspan=1>560</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 55.6% (139/250)     95% CI: 49.2%61.8%Specificity: 98.5% (449/456)     95% CI: 96.7%99.3%</td></tr></table>

Indeterminate gliadin IgA results considered as positive:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Celiac Disease Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>176</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>444</td><td rowspan=1 colspan=1>530</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=4>Sensitivity: 65.6% (164/250)     95% CI: 59.3%71.4%Specificity: 97.4% (444/456)     95% CI: 95.3%-98.6%</td><td rowspan=1 colspan=1></td></tr></table>

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=2 colspan=3></td><td rowspan=1 colspan=2>Celiac Disease Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=2>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>186</td></tr><tr><td rowspan=1 colspan=1>dy</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>494</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>706</td></tr></table>

Indeterminate gliadin IgG results considered as negative:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Celiac Disease Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>186</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>441</td><td rowspan=1 colspan=1>520</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 68.4% (171/250)     95% CI: 62.2%74.0%Specificity: 96.7% (441/456)      95% CI: 94.5%98.1%</td></tr></table>

Indeterminate gliadin $\mathrm { I g G }$ results considered as positive:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Celiac Disease Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>176</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>494</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 76.4% (191/250)     95% CI: 70.5%-81.4%Specificity: 95.4% (435/456)     95% CI: 92.9%97.1%</td></tr></table>

The clinical sensitivity and specificity of the ImmuLisa™ Enhanced Gliadin Antibody ELISAs in this sample cohort are summarized in the following tables for dermatitis herpetiformis:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Dermatitis HerpetiformisDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>ImmuLisaTEnhancedGliadin IgA AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>444</td><td rowspan=1 colspan=1>473</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>501</td></tr><tr><td rowspan=1 colspan=5>* dermatitis herpetiformis (n=45) and non-target disease group (n=456)</td></tr></table>

Indeterminate gliadin IgA results considered as negative:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Dermatitis HerpetiformisDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>449</td><td rowspan=1 colspan=1>479</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>501</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 33.3% (15/45)      95%CI: 20.4%49.1%Specificity: 98.5% (449/456)  95% CI: 96.7%-99.3%</td></tr></table>

Indeterminate gliadin IgA results considered as positive:

ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Dermatitis HerpetiformisDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgA AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>444</td><td rowspan=1 colspan=1>473</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>501</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 35.6% (16/45)     95% CI: 22.3%51.3%Specificity: 97.4% (444/456)  95% CI: 95.3%-98.6%</td></tr></table>

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Dermatitis HerpetiformisDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>ImmuLisaTMEnhancedGliadin IgG AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>454</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>501</td></tr></table>

Indeterminate gliadin $\mathrm { I g G }$ results considered as negative:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Dermatitis HerpetiformisDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>441</td><td rowspan=1 colspan=1>461</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>501</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 55.6% (25/45)     95% CI: 40.1%70.0%Specificity: 96.7% (441/456) 95% CI: 94.5%98.1%</td></tr></table>

Indeterminate gliadin $\mathrm { I g G }$ results considered as positive:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Dermatitis HerpetiformisDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisaTM EnhancedGliadin IgG AntibodyELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>454</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>456</td><td rowspan=1 colspan=1>501</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 57.8% (26/45)     95% CI: 42.2%72.0%Specificity: 95.4% (435/456) 95% CI: 92.9%97.1%</td></tr></table>

4. Clinical cut-off: Refer to assay cut-off.

5. Expected values/Reference range:

Test results in a normal population are expected to be negative. However, it has been determined that some apparently healthy, asymptomatic individuals may test positive for gliadin IgA or gliadin IgG (Rashtak S. et al. Clin Gastroenterol Hepatol. 2008; 6:426-432).

A total of 269 normal human sera (130 pediatrics and 139 adults) tested with the ImmuLisa™ Enhanced Gliadin Antibody ELISAs yielded 8 $( 3 \% )$ positive results for gliadin IgA (all adults) and 10 $( 3 . 7 \% )$ positive for gliadin IgG (4 pediatrics and 6 adults).

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.